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Abstract. Stress-induced hyperglycemia is prevalent in critical care,
even in patients with no history of diabetes. Control of blood glucose
level with tight insulin therapy has been shown to reduce incidences of
hyperglycemia leading to reduced mortality and improved clinical out-
comes. STAR is a tablet-based glucose control protocol with a special-
ized user interface into which insulin and nutrition information can be
entered and predicted. This research describes the first clinical pilot trial
of STAR approach in International Islamic University Hospital, Kuantan,
Pahang. The clinically specified target for blood glucose level is between
4.4 and 8.0 mmol/L. Seven episodes (359 hours) were recruited based
on the need for GC. Overall, 43.93% of measurement are in the range of
4.4-8.0 mmol/L band. The BG median is 8.30 [6.32 - 10.00] mmol/L with
only 1 patient having below than 2.22 mmol/L which is the guaranteed
minimum risk level. This pilot study shows that STAR protocol is a pa-
tient specific approach that provides a good glycemic control in critically
ill patients. Nevertheless, its implementation in Malaysian intensive care
environments require modifications and improvements in certain areas.
Keywords: Glycemic Control; Model-Based Approach; Hyperglycemia; Criti-
cal Care; Clinical Trial.
1 Introduction
Stress-induced hyperglycemia is common in critically ill patients, even among
those without diabetes mellitus [1,2,3,4]. The metabolic response to stress is
characterized by major changes in glucose metabolism. Hyperglycemia is not
only a marker for severity of illness, it also worsens outcomes, leading to an
increased risk of further complications, such as severe infections [5], myocardial
infarctions [6], polyneuropathy and multiple-organ failure [3]. Glucose Control
(GC) has been shown to reduce intensive care unit (ICU) patient mortality up to
45% [3,7,8,9]. However, other GC studies have shown the difficulty in reproducing
the reduced risk of death in patients [10,11,12]. A recent study showing glycemic
outcome is a function of GC given and not of patient condition [13] has reopened
debate on GC and how to apply it safely and effectively.
The Stochastic TARgeted (STAR) protocol is based on a clinically validated
model [14,15] to provide specific recommendations for insulin, as well as nutri-
tion, while controlling hyperglycemia and ensuring a maximum of 5% of the
risk of light hypoglycemia [16,17]. STAR is an adaptable model-based control
approach that empowers versatile, patient-specific GC. It is applied over a range
of clinical conditions and is used for real-time bedside care. Since 2010, two
hospitals have been using STAR protocol as standard of care for GC in their
ICUs namely Christchurch hospital, New Zealand and Kálmán Pándy Hospital,
Hungary.
This paper presents a STAR protocol modulating only insulin infusions to-
ward a targeted glycemia range of 4.4 to 8.0 mmol/L. The initial pilot trial
results of the protocol are compared with the simulations using the same pa-
tients data. This pilot trial tests the ability to adapt the model-based STAR GC
framework from its development environment at Christchurch Hospital in New
Zealand to the International Islamic University Malaysia (IIUM) Hospital ICU
which has an ethnically different cohort and culturally different clinical practice.
2 Method
2.1 STAR Protocol
STAR uses a time varying insulin sensitivity to capture changes in patient con-
dition and insulin-nutrition metabolism over time. Starting criteria for STAR is
two BG measurements over 8 mmol/L within a 4-hour period. The benchmarked
BG target range of STAR is set at 4.4 - 8.0 mmol/L based on reduced risks
with inreased BG in intermediate bands. STAR specifically captures developing
physiological patient condition and inter- and intra-patient fluctuation by iden-
tifying insulin sensitivity (SI) and its future variabillity to optimize safety and
GC performance. Its elements can be modified according to clinically determined
glycemic targets, control approaches (e.g. insulin only, insulin and nutrition, etc.)
and clinical resources (e.g. measurement frequency).
STAR is implemented in tablet computer to provide specialized user interface
into which nutrition and insulin information can be entered. Once BG measure-
ments are taken, an insulin sensitivity profile can be computed. Insulin sensitivity
varies hourly, and stochastic based forecasting is used to determine likely out-
comes in insulin sensitivity for any possible insulin and/or nutrition input. This
forecasting allows changes in future insulin sensitivity to be determined.
The insulin-nutrition combination that best overlaps the resulting BG range
with the target clinical band is selected by placing the 5th percentile BG out-
come on the lower edge of the clinically specified target range. STAR seeks to
maximize nutrition delivery while dosing insulin in this context. If, for maximum
nutritional and insulin treatments, the BG outcome range does not sufficiently
overlap the clinical target range, then STAR will recommend a drop in nutrition
to maintain GC and reduce risk [17]. The nutrition will be raised back to its
goal feed value as soon as possible. In cases where the feed must be clinically
determined or switched off, STAR can be set to give insulin recommendations
only. Figure 1 summarizes how STAR functions.
Fig. 1: Summary of the STAR functions. SI is the insulin sensitivity, BG is blood
glucose.
2.2 Pilot Trial
In this first pilot trial for Malaysian critically ill patients, seven episodes (of 359
hours) from four non-diabetic patients was controlled using STAR. These were
obtained during their ICU stay in the first semester of 2017. Patient 1 and 2
had more than one episodes as they were taken off GC using STAR tablet due
to judgement by medical staffs who were new to its use. The selection criteria
includes GC for a minimum of 24 hours. Table 1 shows the baseline for each
episode (age, sex, hours, initial BG and diagnosis). Written informed consent
was obtained for all patients, and approval (IREC 657) was granted for this
study by IIUM Research Ethics Committee and National Institute of Health
(NIH).
Table 1: Baseline clinical data of all four patients and corresponding to seven
episodes.
Patient Age Sex Hours Initial BG Diagnosis
1a 56 F 58 14.4 Congestive Heart Failure, Lung Fibrosis Mixed Connective Tissue Disease,
Acute Pulmonary Oedema, Billateral Parenchymal Disease1b 56 F 46 10.2
21 49 M 71 11.0
Motor Vehicle Accident with Polytrauma Hyper Tension2b 49 M 28 11.6
2c 49 M 85 11.7
3 70 M 33 17.4
Early Glottic CA, Left vocal Cord, Heart Disease Hyper Tension,
Diabetes Mellitus
4 66 F 38 11.8 Hospital required Pneumonia, Renal Cell Carcinoma with Brain Metastasis
For each patient, the trial started with a BG measurement made by nursing
staff. BG measurements were made using B-Braun glucometers. The approach
then identifies a new insulin and nutrition infusion rate, which was then given
by the nurse. The time interval until the next BG measurement is also selected
by the medical staffs based on 1-3 hourly treatment options offered.
2.3 Virtual Trial
To analyze the compliance of STAR as clinically applied GC protocol, a virtual
trial was conducted using the clinical data. This trial has two phases: i) Fitting
and ii) Simulation. During the fitting, clinical data were used to identify hourly SI
values which served as a virtual patient profile. This profile reflects the glycemic
response to insulin and nutrition inputs and can be used to simulate responses
to different interventions with good accuracy [15,18]. In the second phase, the
profile was used to simulate glycemic response to STAR as simulated, where
differences indicates non-compliance to STAR.
3 Results
Clinical results are summarized by whole cohort statistics in Table 2. There were
239 BG measurements taken during 359 hours of control. BG median value, 8.3
mmol/L for whole cohort is higher than BG target of 8.0 mmol/L. BG levels
are relatively widely distributed, as evidenced by the IQR range (25th–75th per-
centile value) of 4.68 mmol/L for the cohort, and the 25–75% confidence interval
across patients in Figure 2. Table 2 shows that 43.93% of BG measurements are
between 4.4 to 8.0 mmol/L. The control is tight in this band, as illustrated by
the steep slope of BG Cumulative Distributive Function (CDF) for the whole
cohort in Figure 2 and similar per-patient CDFs. There was only one patient
with severe hypoglycemic (measurement BG < 2.22 mmol/L) which was patient
2b.
Virtual trial results are also presented in Table 2. The total number of BG
measurements is significantly reduced by 36, from an average 16 per-day to the
13 per-day that matches STAR in use else where [19]. Overall statistics for BG
measurements recorded better numbers than clinical results. 66.50% patients are
between target range of 4.4 to 8.0 mmol/L and only 7.88% of patients with BG
> 10.0 mmol/L. There is no episode of severe hypoglycemia.
Table 2: Cohort blood glucose results based on clinical data and the virtual trial.
Whole cohort statistics Clinical Data Virtual trial
Number of episodes: 7 7
Total hours: 359 hours 359 hours
Number of BG measurements: 239 203
BG median [IQR] (mmol/L): 8.30 [6.32 - 10.00] 6.80 [5.50 - 8.07]
BG mean (geometric) (mmol/L): 7.86 6.64
BG Standard Deviation (geometric) (mmol/L): 1.39 1.35
% BG within 4.0 - 6.1 mmol/L: 23.85 38.91
% BG within 4.4 - 7.0 mmol/L: 29.71 47.78
% BG within 4.4 - 8.0 mmol/L: 43.93 66.50
% BG within 8.0 - 10.0 mmol/L: 28.03 18.22
% BG >10.0 mmol/L: 23.85 7.88
% BG <4.4 mmol/L: 5.02 8.37
% BG <4.0 mmol/L: 1.67 5.42
% BG <2.22 mmol/L: 0.42 0
Number of patients <2.22 mmol/L: 1 0
Median insulin rate [IQR] (U/hr): 2.0 [1.0 - 3.8] 3.0 [1.5 – 6.0]
Median glucose rate [IQR] (g/hour): 6.0 [4.9 - 8.3] 5.5 [3.9 – 6.6]
Clinical results are provided for all individual episodes in Table 3 and Figure
3. Overall, these results indicate that these specific patients were particularly
insulin resistant. In addition, the pilot trial length was not sufficient to achieve
consistently high percentages of BG levels in a tight band around the target
where resistance and variability decline significantly after 48-72 hours. In this
trial, only one episode exceeds this length (episode 2c).
4 Discussion
The objective of this pilot trial is to look at the initial assessment of perfor-
mance, safety and compliance of STAR in a Malaysian ICU. This trial was
started off using a benchmarked BG target range of 4.4 – 8.0 mmol/L. Over-
all results suggest that the protocol can be considered to be used in Malaysian
intensive care. However, the clinical performance assessment in Table 2 where
a significant 23.85% of BG level above 10.0 mmol/L and 28.03% of BG level
within 8.0 - 10 mmol/L raises the question of whether to put a different target
range for Malaysian patients. Results from virtual trial shows percentage of light
hypoglycaemia is above 5% (8.37% for BG <4.4 mmol/L and 5.42 % for <4.0
mmol/L) also suggest the same proposition.
Fig. 2: Median, 25-75% and 5-95% intervals of per-patient BG Cumulative Dis-
tribution Functions (CDFs) defined on whole cohort.
This pilot clinical trial is the first attempt to use STAR protocol in a Malaysian
ICU. Another important result is one patient episode with severe hypoglycemia
(BG < 2.22 mmol/L). Figure 4a shows episode 2b profile with hypoglycemia. The
results for this episode 2b were re-simulated and the new outcome is shown in
Figure 4b. It demonstrates no hypoglycemia. In fact, this patient has an overall
low insulin sensitivity. He was admitted with polytrauma secondary to motor-
vehicle accident. One main difference comes from the number of BG measure-
ment (26 in clinical trial vs. 23 in simulation) which modifies iterative forecasting
of insulin and nutrition input towards patient. As a result, clinical patient has
higher BG measurement even though still in target range and a rise in insulin
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Fig. 3: Per-patient CDFs of BG concentration.
sensitivity is recorded before the hypoglycemia is detected. More differences can
be seen on the proposition for insulin and nutrition input. These differences
question the nurses’ compliance during clinical implementation.
5 Conclusion
This pilot study shows the results of our inital attempt of using Stochastic TAR-
geted (STAR) protocol in the intensive care unit, IIUM hospital. We demon-
strated that this approach was able to provide a good blood glucose control
among critically ill Malaysian patients and was adaptable according to patients’
clinical condition. We have identified specific issues that warrant modification of
the protocol in order to improve its performance, if it is to be used in future tri-
als. This is to ensure its safety and efficiency in achieving good glycemic control
in Malaysian ICU population.
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(a) Clinical results
(b) Clinical data re-simulated with STAR protocol
Fig. 4: Patient 2b profiles.
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